Methods of treatment involving p21/CIP1

Abstract

The onset ratios and pathological conditions of collagen-induced arthritis and adjuvant arthritis in model mice and rats, respectively, were successfully ameliorated by topically expressing the cyclin-dependent kinase inhibitors p16INK4a and p21Cip1 p in articular tissues using adenoviral vectors. In the synovial cells of CDKI-transduced mice, expression of inflammatory cytokines was inhibited. Described are the use of the p21Cip1 protein for inhibiting abnormal proliferation of synovial tissues, inflammation in synovial tissues and / or expression of inflammatory cytokines in synovial tissues; the p21Cip1 gene; compounds promoting the activity or expression of the p21Cip1 protein; and pharmaceutical compositions containing these molecules. Also provided are method of screening for compounds participating in the abnormal proliferation of synovial tissues, inflammation in synovial tissues and / or the expression of inflammatory cytokines in synovial tissues targeting the p21Cip1 protein. Rheumatoid arthritis and other disorders associated with inflammation of the synovial tissue can be prevented or treated by promoting expression or function of p21Cip1 protein.

Description

CLAIM OF PRIORITY[0001]This application is a continuation of U.S. patent application Ser. No. 10 / 088,661, filed on Jul. 19, 2002, which is the U.S. National Phase of International Patent Application No. PCT / JP00 / 06511, filed on Sep. 22, 2000, which claims the benefit of Japanese Patent Application No. 11-269579, filed on Sep. 22, 1999. The entire contents of each of the foregoing applications are hereby incorporated by reference.TECHNICAL FIELD[0002]The present invention relates to molecules for suppressing inflammation of Rheumatoid arthritis (RA) and the screening of those molecules.BACKGROUND ART[0003]Rheumatoid arthritis (RA) is characterized by the synovial inflammation of multiple joints. The affected synovial tissues contain activated macrophages, fibroblasts, T- and B-lymphocytes. The synovial fibroblasts proliferate and release tissue-degrading enzymes in response to pro-inflammatory cytokines, such as interleukin (IL)-1β, tumor necrosis factor (TNF)-α, and IL-6, which are ...

AI Technical Summary

Benefits of technology

[0012]From these results, the present inventors discovered that the induction of CDKI gene expression in rheumatic synovial tissue, especially the induction of p21Cip1, may be an effective strategy for the treatment of RA, and that the ectopic expression of CDKI not only prevents overgrowth of synovium but also mitigates inflammation induction environment in morbid joint. Moreover, these findings suggest that synthetic compounds and such which selectively promote expression of p16INK4a or p21Cip1 also function as a therapeutic reagent toward RA. Such compounds, which can regulate aberrant growth of synovial cells or inflammation of synovium, can be efficiently screened by targeting the p21Cip1 protein. Moreover, application toward the prevention or the therapy of diseases caused from aberrant growth and / or inflammation of synovial cells, such as RA, is expected for the p21Cip1 protein, the p21Cip1 gene, and compounds obtained by such screening.

[0053]Then, the constructed vector is transfected into mammalian cells, and said cells are contacted with a test sample to detect the reporter activity. Test samples are not limited specifically to those for the screening methods described above. The detection of the reporter activity can be conducted by well known method according to the type of the reporter gene. As a result, compounds which promote the expression of the p21Cip1 gene and inhibit aberrant growth of synovial tissue, inflammation of synovial tissue, and / or the expression of inflammatory cytokines in synovial tissue can be screened by selecting compounds which increase reporter activity as compared to the reporter activity in the cells that were not contacted with the test sample. The screening method has a feature that it is simple as compared to the screening using direct detection method, such as northern blotting method or RT-PCR analysis described above, since the expression of p21Cip1 gene is detected using a reporter activity as an index.

Problems solved by technology

Most patients respond well to these drugs, but some are resistant or the effect of these drugs decreases after a period of disease remission in other patients.

Moreover, there is little evidence proving that these drugs arrest the progression of the disease in the long run.

It is presumed that the suppression of one inflammatory mediator might activate other mediators because of the complexity and redundancy of the inflammatory pathways.

Therefore, it is believed that the total prevention of joint destruction is not available through conventional treatments.

Images